Consultado el 1 de junio de 2007
10.1161/CIR.0000000000000659 42 BentingerM.BrismarK.DallnerG
More research is needed to determine the best approach to monitoring and managing these patients once the medication is discontinued. According to Maya and colleagues, current evidence on links between GLP-1s and pregnancy complications remain limited, conflicting and subject to residual confounding by indication or selection and recall bias. They added that if gestational weight gain is a result of GLP-1 discontinuation before or early during pregnancy, negative outcomes for the parent-child dyad could result. In the retrospective analysis, the researchers assessed outcomes among 149,790 singleton pregnancies delivered between June 1, 2016, and March 31, 2025
Ending obesity coverage for GLP-1 obesity drugs could improve the states finances but might also result in health inequities and less comprehensive coverage, the states health and human services agency acknowledged in its September budget request
Los estudios clnicos demuestran que el efecto de los agonistas de GLP-1 va ms all de la balanza, impactando favorablemente en la salud metablica general: Ayuda a llenarse con menos cantidad de comida y a mantener la saciedad durante ms tiempo despus de almorzar o cenar